Drug sponsors gave a less than overwhelming endorsement of orphan incentives to the US Government Accountability Office, a potentially concerning revelation for advocates and other stakeholders.
The sample size was small (only four manufacturers were interviewed for the GAO study) but two of the sponsors...







